Literature DB >> 28393181

MicroRNA-based molecular classification of papillary thyroid carcinoma.

Francesca Rosignolo1, Lorenzo Memeo2, Fabio Monzani3, Cristina Colarossi2, Valeria Pecce1, Antonella Verrienti1, Cosimo Durante1, Giorgio Grani1, Livia Lamartina1, Stefano Forte4, Daniela Martinetti4, Dario Giuffrida2, Diego Russo5, Fulvio Basolo6, Sebastiano Filetti1, Marialuisa Sponziello1.   

Abstract

MicroRNA (miRNA) expression is dysregulated in many human malignancies, and a growing number of studies are focused on their potential use as tumor biomarkers. To identify a miRNA signature for papillary thyroid carcinomas (PTC), we investigated miRNA expression profiles in two independent cohorts of PTCs, which included major histological subtypes [classical-type (PTC‑CT), follicular-variant (PTC‑FV), and tall-cell variant (PTC‑TCV)] and cases with low or intermediate risk of recurrence. Using TaqMan® Array Human MicroRNA A+B Cards v3.0, we first performed microRNA profiling of normal and neoplastic thyroid tissues from 29 PTC patients. Promising candidates were then investigated in a second, independent cohort of 76 PTCs using Custom TaqMan® Array MicroRNA Cards. We identified a molecular signature of 11 miRNAs that were significantly upregulated (miR‑146b-5p, miR‑146b-3p, miR‑221-3p, miR‑222‑5p, miR‑222‑3p) or downregulated (miR‑1179, miR‑486‑5p, miR‑204-5p, miR‑7-2-3p, miR‑144-5p, miR‑140-3p) in PTC tissues vs. normal thyroid tissue. Upregulation of miR‑146b-5p and miR‑222‑3p was also significantly associated with an increased risk of recurrence. Higher than normal expression of miR‑146b-5p and miR‑146b-3p characterized PTC‑CT and PTC‑TCV but not PTC‑FV, whereas miR‑21-5p was significantly upregulated only in PTC‑TCV. When PTC‑FV were subclassified as encapsulated (PTC‑EFV) or infiltrative (PTC‑IFV), miR‑204-5p was downregulated in all histological subtypes except PTC‑EFV, which displayed expression levels similar to those of normal thyroid tissues. These findings provide new insights into the molecular classification of PTC, showing that different miRNA expression profiles are associated with different histological types of PTC and different risks of recurrence.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28393181     DOI: 10.3892/ijo.2017.3960

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  34 in total

Review 1.  Phytochemicals in thyroid cancer: analysis of the preclinical studies.

Authors:  Stefania Bulotta; Francesca Capriglione; Marilena Celano; Valeria Pecce; Diego Russo; Valentina Maggisano
Journal:  Endocrine       Date:  2021-02-15       Impact factor: 3.633

2.  Analytical validation of a novel targeted next-generation sequencing assay for mutation detection in thyroid nodule aspirates and tissue.

Authors:  Antonella Verrienti; Valeria Pecce; Luana Abballe; Valeria Ramundo; Rosa Falcone; Farzaneh Inanloo Nigi Jak; Chiara Brunelli; Guido Fadda; Daniela Bosco; Valeria Ascoli; Raffaella Carletti; Cira Di Gioia; Giorgio Grani; Marialuisa Sponziello
Journal:  Endocrine       Date:  2020-06-06       Impact factor: 3.633

3.  Analysis of serum microRNA in exosomal vehicles of papillary thyroid cancer.

Authors:  Francesca Capriglione; Antonella Verrienti; Marilena Celano; Valentina Maggisano; Marialuisa Sponziello; Valeria Pecce; Agnese Gagliardi; Laura Giacomelli; Valerio Aceti; Cosimo Durante; Stefania Bulotta; Diego Russo
Journal:  Endocrine       Date:  2021-08-10       Impact factor: 3.633

4.  MiR-203a-3p, miR-204-3p, miR-222-3p as useful diagnostic and prognostic tool for thyroid neoplasia spectrum.

Authors:  Stefana Stojanović; Zorana Dobrijević; Sonja Šelemetjev; Ilona Đorić; Jelena Janković Miljuš; Vladan Živaljević; Tijana Išić Denčić
Journal:  Endocrine       Date:  2022-09-14       Impact factor: 3.925

5.  Effects of nutraceuticals on anaplastic thyroid cancer cells.

Authors:  Lorenzo Allegri; Francesca Rosignolo; Catia Mio; Sebastiano Filetti; Federica Baldan; Giuseppe Damante
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-02       Impact factor: 4.553

6.  Performance of a dual-component molecular assay in cytologically indeterminate thyroid nodules.

Authors:  Guido Fadda; Sebastiano Filetti; Marialuisa Sponziello; Chiara Brunelli; Antonella Verrienti; Giorgio Grani; Valeria Pecce; Luana Abballe; Valeria Ramundo; Giuseppe Damante; Diego Russo; Celestino Pio Lombardi; Cosimo Durante; Esther Diana Rossi; Patrizia Straccia
Journal:  Endocrine       Date:  2020-03-30       Impact factor: 3.633

7.  Anti-oncogenic effects of SOX2 silencing on hepatocellular carcinoma achieved by upregulating miR-222-5p-dependent CYLD via the long noncoding RNA CCAT1.

Authors:  Jian Pu; Xianjian Wu; Yi Wu; Zesheng Shao; Chunying Luo; Qianli Tang; Jianchu Wang; Huamei Wei; Yuan Lu
Journal:  Aging (Albany NY)       Date:  2021-03-22       Impact factor: 5.682

8.  Emerging roles and mechanisms of microRNA‑222‑3p in human cancer (Review).

Authors:  Danhua Wang; Yiwen Sang; Tao Sun; Piaoping Kong; Lingyu Zhang; Yibei Dai; Ying Cao; Zhihua Tao; Weiwei Liu
Journal:  Int J Oncol       Date:  2021-03-24       Impact factor: 5.650

Review 9.  Recent advances in managing differentiated thyroid cancer.

Authors:  Livia Lamartina; Giorgio Grani; Cosimo Durante; Sebastiano Filetti
Journal:  F1000Res       Date:  2018-01-18

Review 10.  The Role of Snail-1 in Thyroid Cancer-What We Know So Far.

Authors:  Katarzyna Wieczorek-Szukala; Andrzej Lewinski
Journal:  J Clin Med       Date:  2021-05-26       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.